• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Oncology Pharma and Ribera Solutions Signed a Licensing Agreement for the Use of Ribera’s Clinical Trials Platform, Connect2Med

Share:

November 11, 2019

Oncology Pharma Inc. (OTCPK: ONPH) is pleased to announce that it has entered into an agreement with Ribera for its clinical trial platform, “Connect2Med”. The license by Ribera of its “Connect2Med” for human clinical trials to Oncology Pharma shall be exclusive for oncology, drug development, clinical trials, personalized oncology and therapeutics worldwide, including the right to sub-license, with one year to complete certain milestones, including modifications for oncology use and an option to purchase the platform or renew the license agreement.

Ribera Solutions is a software services firm focused on the development of technologies for the life sciences, medical devices, healthcare and clinical research sectors. The firm provides technology consulting, research and development on cloud, mobile and web-based connected care solutions. Ribera develops its own proprietary software applications that can be licensed for running clinical trials, providing “connected” care services, and for collection of remote data and analysis.

Dr. Mahant (CSO & COO) stated: “The iOS and Android based mobile “Connect2Med” App is a powerful tool that is centralized, has recruitment features, the potential to improve participant retention, participant tracking, and the App will be in compliance with local and Federal regulations such as HIPAA.”

Dr. Stefan Gruenwald (Scientific Advisor and Board Member, Oncology Pharma, Inc.) believes that Ribera’s Connect2Med is one of the best digital platforms for patient engagement and retention. It is designed to advance clinical trials for pharmaceutical and diagnostic / medical device companies by improving patient retention rate and engagement through real-time communication. Through medical device connectivity patients can schedule and perform tele-health examinations with hospitals and clinics. Powerful artificial intelligence and Smart Health Applications deliver relevant content directly to the user, which can be customized for data analysis and reports in real-time.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Source: Globe News Wire

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Digital Mental Health Clinic Mantra Health Secures $22M to Support University StudentsDigital Mental Health Clinic Mantra Health Secures $22M to Support University Students
  • The University of Queensland, CEPI and CSL Partner to Advance Development and Manufacture of COVID-19 Vaccine CandidateThe University of Queensland, CEPI and CSL Partner to Advance Development and Manufacture of COVID-19 Vaccine Candidate
  • KRY Announces Merger with Swedish Healthcare Company HelsaKRY Announces Merger with Swedish Healthcare Company Helsa
  • Psychedelic Biotech Company Scoops up Research Focused Digital Health Company HealthModePsychedelic Biotech Company Scoops up Research Focused Digital Health Company HealthMode
  • Why SDoH Data is Key for Developing Population Health StrategiesWhy SDoH Data is Key for Developing Population Health Strategies
  • Merck Animal Health Completes Acquisition of Vaki to Further Broaden Its Leadership Position in Aquaculture to Advance Fish Health and WelfareMerck Animal Health Completes Acquisition of Vaki to Further Broaden Its Leadership Position in Aquaculture to Advance Fish Health and Welfare
  • Change Healthcare Launches COVID-19 Research Database Using De-Identified Data to Track Disease ProgressionChange Healthcare Launches COVID-19 Research Database Using De-Identified Data to Track Disease Progression
  • HUG Becomes First European Hospital To Adopt IBM Watson For GenomicsHUG Becomes First European Hospital To Adopt IBM Watson For Genomics

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications